Chronic thromboembolic pulmonary hypertension: current diagnostic and treatment options: A review

Cover Page

Cite item

Full Text

Abstract

The article reviews current approaches to diagnosing and treating chronic thromboembolic pulmonary hypertension (CTEPH). The definition of the CTEPH is given, and its main risk factors are described. It is shown that the modern algorithm of diagnostic search includes four stages; the examination methods used at each stage are characterized. The most rational approach to CTEPH therapy is provided; the possibilities and limitations of pulmonary endarterectomy, transluminal balloon angioplasty of the pulmonary arteries, and specific therapy of pulmonary hypertension in such patients are described. The clinical presentation and treatment of CTEPH according to the Russian Pulmonary Hypertension Registry are reviewed.

About the authors

Irina E. Chazova

Chazov National Medical Research Center of Cardiology

Author for correspondence.
Email: c34h@yandex.ru
ORCID iD: 0000-0002-9822-4357

акад. РАН, доктор медицинских наук, профессор, заместитель генерального директора по научно-экспертной работе, руководитель отдела Гипертонии

Russian Federation, Moscow

References

  1. Чазова И.Е., Мартынюк Т.В., Валиева З.С., и др. Европейские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский кардиологический журнал. 2021;1:6-43 [Chazova IE, Martyniuk TV, Valieva ZS, et al. Eurasian Guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal. 2021;1:6-43 (in Russian)]. doi: 10.38109/2225-1685-2021-1-6-43
  2. Валиева З.С., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Характеристика пациентов с хронической тромбоэмболической легочной гипертензией по данным Российского национального регистра. Терапевтический архив. 2021;93(9):1058-65 [Valieva ZS, Martynyuk TV, Nakonechnikov SN, Chazova IE. Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(9):1058-65 (in Russian)]. doi: 10.26442/00403660.2021.09.201037
  3. Valerio L, Mavromanoli AC, Barco S, et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: The FOCUS study. Eur Heart J. 2022;43(36):3387-98. doi: 10.1093/eurheartj/ehac206
  4. Яровой С.Ю., Чазова И.Е., Матчин Ю.Г., и др. Показатели острой фармакологической пробы у пациентов с хронической тромбоэмболической легочной гипертензией после транслюминальной баллонной ангиопластики легочных артерий. Системные гипертензии. 2020;17(3):53-8 [Yarovoy SY, Chazova IE, Matchin YG, et al. Parameters of acute vasoreactivity testing after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2020;17(3):53-8 (in Russian)]. doi: 10.26442/2075082X.2020.3.200418
  5. Яровой С.Ю., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Cтруктурные изменения легочных артерий после транслюминальной баллонной ангиопластики у пациентов с хронической тромбоэмболической легочной гипертензией. Евразийский кардиологический журнал. 2020;4:12-20 [Yarovoy SY, Danilov NM, Matchin YG, Chazova IE. Structural changes of the pulmonary arteries after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Eurasian Heart Journal. 2020;4:12-20 (in Russian)]. doi: 10.38109/2225-1685-2020-4-12-20
  6. Wilkens H, Konstantinides S, Land IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated recommendations from the Colone Consensus Conference 2018. Int J Cardiol. 2018;272S:69-78. doi: 10.1016/j.ijcard.2018.08.079
  7. Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001;103(1):10-3. doi: 10.1161/01.cir.103.1.10
  8. Kataoka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5(6):756-62. doi: 10.1161/CIRCINTERVENTIONS.112.971390
  9. Данилов Н.М., Яровой С.Ю., Елфимова Е.М., и др. Клинические и рентгенологические аспекты реперфузионного отека легких после транслюминальной баллонной ангиопластики легочных артерий у пациентов с хронической тромбоэмболической легочной гипертензией. Системные гипертензии. 2022;19(3):23-30 [Danilov NM, Yarovoy SY, Elfimova EM, et al. Clinical and radiological aspects of reperfusion pulmonary edema after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2022;19(3):23-30 (in Russian)]. doi: 10.38109/2075-082X-2022-3-23-30
  10. Sunthralingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest. 2008;134(2):229-36. doi: 10.1378/chest.07-2681
  11. Jaïs X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension BENEFIT (bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. doi: 10.1016/j.jacc.2008.08.059
  12. Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): Results from the multicenter, phase 2, randomized, double blind, placebo controlled study. Lancet Respir Med. 2017;5(10):785-94. doi: 10.1016/S2213-2600(17)30305-3
  13. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-9. doi: 10.1056/NEJMoa020204
  14. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. doi: 10.1056/NEJMoa1209657

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies